Table 2.

Comparison of Clinical Features According to PAK4 Expression.

	No. cases (N = 49)	PAK4 Expression
		Positive (n = 4)	Negative (n = 45)	P
Age (years)
≤60	35 (70.8%)	3 (75.0%)	32 (70.5%)	N-C
>60	14 (29.2%)	1 (25.0%)	13 (29.5%)
Lauren type
Intestinal	7 (14.3%)	0 (0%)	7 (15.6%)	N-C
Diffuse	7 (14.3%)	1 (25.0%)	6 (13.3%)
Mixed	2 (4.1%)	0 (0%)	2 (4.4%)
Unknown	33 (67.3%)	3 (75.0%)	30 (66.7%)
Lymphovascular invasion
Presence	14 (28.6%)	1 (25.0%)	13 (28.9%)	N-C
Absence	1 (2.0%)	0 (0%)	1 (2.2%)
Unknown	34 (69.4%)	3 (75.0%)	31 (68.9%)
Histologic diagnosis
Adenocarcinoma	33 (67.3%)	3 (75.0%)	30 (66.7%)	N-C
Signet ring cell carcinoma	16 (32.7%)	1 (25.0%)	15 (33.3%)
Best response to capecitabine/cisplatin chemotherapy
CR/PR	12 (24.5%)	0 (0.0%)	11 (24.4%)	N-C
SD	28 (57.1%)	3 (75.0%)	25 (55.6%)
PD	7 (14.3%)	1 (25.0%)	7 (15.6%)
Not evaluated	2 (4.1%)	0 (0%)	2 (4.4%)
Metastatic sites
Confined to intraperitoneuthem (peritoneum, omentum, ascites, ovary, intra-abdominal lymph node)	36 (73.5%)	3 (75.0%)	33 (73.3%)	N-C
Extraperitoneal organs (lung, liver, bone)	13 (26.5%)	1 (25.0%)	12 (26.7%)

CR indicates complete remission; N-C, not contributable; PD, progressive disease; PR, partial remission; SD, stable disease.